Founded in 2007, Lucid Group provides medical education, medical communication, strategic consultancy and digital services to clients. The company has offices in London, Beaconsfield and NYC and employs over 100 people.
The investment will enable Lucid to continue to build infrastructure to support its rapid growth and build market presence in the US.
"As the pharmaceutical sector landscape becomes increasingly complex and challenging, it's more important than ever to ensure healthcare professionals are supported to make the correct interventions to improve their patient's health, based on the latest evidence available.
We felt the time was right to bring on board a strategic partner, and in LDC we have an experienced investor with a strong track record in the healthcare sector. From the outset, they have had a flexible approach to the investment, structuring the deal on terms that worked for us.
We're now best placed to maximise the growth potential of Lucid and solidify our position as thought leaders and innovators in the medical education market."
Dennis O'Brien, CEO, Lucid